Faldaprevir

Faldaprevir
Clinical data
Other names	BI 201335
Routes of; administration	By mouth
ATC code	J05AP04 (WHO) ;
Legal status
Legal status	Abandoned;
Identifiers
	IUPAC name N-[(Cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-({8-bromo-2-[2-(isobutyrylamino)-1,3-thiazol-4-yl]-7-methoxy-4-quinolinyl}oxy)-N-[(1R,2S)-1-carboxy-2-vinylcyclopropyl]-L-prolinamide;
CAS Number	801283-95-4;
PubChem CID	42601552;
DrugBank	DB11808;
ChemSpider	26327117;
UNII	958X4J301A;
ChEMBL	ChEMBL1241348;
CompTox Dashboard (EPA)	DTXSID20230084 ;
Chemical and physical data
Formula	C40H49BrN6O9S
Molar mass	869.83 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)C(=O)Nc1nc(cs1)c2cc(c3ccc(c(c3n2)Br)OC)O[C@@H]4C[C@H](N(C4)C(=O)[C@H](C(C)(C)C)NC(=O)OC5CCCC5)C(=O)N[C@@]6(C[C@H]6C=C)C(=O)O;
	InChI InChI=1S/C40H49BrN6O9S/c1-8-21-17-40(21,36(51)52)46-34(49)27-15-23(18-47(27)35(50)32(39(4,5)6)44-38(53)56-22-11-9-10-12-22)55-29-16-25(26-19-57-37(43-26)45-33(48)20(2)3)42-31-24(29)13-14-28(54-7)30(31)41/h8,13-14,16,19-23,27,32H,1,9-12,15,17-18H2,2-7H3,(H,44,53)(H,46,49)(H,51,52)(H,43,45,48)/t21-,23-,27+,32-,40-/m1/s1; Key:LLGDPTDZOVKFDU-XUHJSTDZSA-N;

Faldaprevir was an experimental drug for the treatment of hepatitis C (HCV). It was being developed by Boehringer-Ingelheim and reached Phase III clinical trials in 2011.[1] Boehringer announced in 2014 that it would not pursue approval of the drug any more because of better HCV treatments having become available.[2]

Mechanism of action

Faldaprevir is a hepatitis C virus protease inhibitor.

Studies

Faldaprevir was tested in combination regimens with pegylated interferon and ribavirin, and in interferon-free regimens with other direct-acting antiviral agents including deleobuvir.

Data from the SOUND-C2 study, presented at the 2012 AASLD Liver Meeting, showed that a triple combination of faldaprevir, deleobuvir, and ribavirin performed well in HCV genotype 1b patients.[3] Efficacy fell below 50%, however, for dual regimens without ribavirin and for genotype 1a patients.

References

Clinical trial number NCT01343888 for "Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)" at ClinicalTrials.gov
"Hepatitis C: Aus für Boehringers Faldaprevir". www.pharmazeutische-zeitung.de.
Interferon-free hepatitis C treatment with faldaprevir proves safe and effective in people with cirrhosis. Alcorn, K. Aidsmap.com. 20 November 2012.

External links

Faldaprevir at chem.sis.nlm.nih.gov
Faldaprevir at chemicalregister.com

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Clinical trial number NCT01343888 for "Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)" at ClinicalTrials.gov

[2] "Hepatitis C: Aus für Boehringers Faldaprevir". www.pharmazeutische-zeitung.de.

[3] Interferon-free hepatitis C treatment with faldaprevir proves safe and effective in people with cirrhosis. Alcorn, K. Aidsmap.com. 20 November 2012.